Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) [Phase 3]

View source ↗

Summary

A Phase 3 trial sponsored by Bayer evaluated VEGF Trap-Eye (aflibercept) for central retinal vein occlusion; results have been posted after the study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• VEGF Trap-Eye (aflibercept)

Snippet

Sponsor: Bayer | Conditions: Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2012-11-22